Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JPM 2025
Biotech
Cullinan CEO sets tone for bispecific's upcoming lupus readout
While CAR-T's 100% remission rate has set the benchmark in lupus, Cullinan's CEO argues the bar is “very different” for an off-the-shelf regimen.
Angus Liu
Feb 7, 2025 5:00am
What to expect from the biotech IPO market in 2025
Jan 31, 2025 9:15am
Why biotechs can benefit from the 'rational' IPO environment
Jan 24, 2025 10:30am
Takeda's R&D head shares 'new way of working'
Jan 21, 2025 4:48pm
Biopharma largely unfazed by security concerns for JPM25
Jan 17, 2025 11:10am
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
